Article
Many hospitalized patients with type 2 diabetes and mild hyperglycemia on admission can be managed with sliding scale insulin alone
Publish date: January 7, 2022
Dr. Knees Clinical question: In patients with mild hyperglycemia on admission, can sliding...
READ MORE >News
Care via video teleconferencing can be as effective as in-person for some conditions
Publish date: December 6, 2021
Video teleconferencing works best for monitoring patients with chronic conditions, according to the author of a new paper.
READ MORE >News
SGLT2 inhibitor use tied to fewer atrial arrhythmias
Publish date: December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
READ MORE >News
Empagliflozin a winner in challenging arena of stabilized acute HF
Publish date: November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
READ MORE >News
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
Publish date: November 17, 2021
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
READ MORE >News
Some diabetes drugs may lower risk of severe COVID-19 outcomes
Publish date: October 19, 2021
Glucose-regulating medications may improve outcomes in COVID-19 patients with type 2 diabetes, a multinational retrospective cohort study suggests.
READ MORE >News
Age, C-reactive protein predict COVID-19 death in diabetes
Publish date: September 29, 2021
“This means we can easily identify patients early on in their hospital stay who will likely require more aggressive interventions to try and improve survival.”
READ MORE >News
Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs
Publish date: September 27, 2021
SGLT2 inhibitor versus GLP-1 RA use was associated with a significantly lower rate of hospitalization for heart failure in people with diabetes.
READ MORE >News
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
Publish date: September 20, 2021
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say forget that.
READ MORE >News
PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF
Publish date: September 14, 2021
The SGLT2 inhibitor dapagliflozin boosted KCCQ scores and 6-minute walk distance in HFpEF patients in a 324-patient randomized trial.
READ MORE >
